July 21, 2020—GenMark Diagnostics announced that its ePlex Respiratory Pathogen 2 Panel is available for U.S. commercial distribution and clinical use.
The ePlex RP2 Panel is a rapid-result multiplex panel test that can identify 21 pathogens, including SARS-CoV-2, influenza, adenovirus, rhinovirus, and respiratory syncytial virus, in less than two hours.
“One recent study highlighted that about 20 percent of COVID-19 patients are also infected with other respiratory pathogens,” Scott Mendel, president and CEO of GenMark, said in a press statement. “Syndromic panels that provide broad coverage of viruses and bacteria from one patient sample will be critical this flu season, which is expected to coincide with continued SARS-CoV-2 infections.”
The panel is designed for use with the GenMark’s ePlex system. The company has submitted an EUA to the Food and Drug Administration for the ePlex RP2 Panel.